American College of Clinical Pharmacy
      Search      Cart

Pediatrics PRN Focus Session -- Medical Use of Cannabinoid Products in the Pediatric Population

Sunday, October 27, 2019 from 4:30 PM to 6:00 PM EDT at 3rd Floor: Mercury Ballroom

Available for 1.50 hours of CPE credit
Activity Number: 0217-0000-19-180-L01-P
Activity Type: An Application-Based Activity

Medical Use of Cannabinoids in Epilepsy and Beyond
4:30 PM

  • Christopher T. Campbell, Pharm.D., BCPPSSpeaker: Christopher T. Campbell, Pharm.D., BCPPS
    Clinical Assistant Professor, University of Florida, Gainesville, Florida
      View Biography

Learning Objectives
1. Describe the use of cannabidiol oil and FDA-approved solution in management of epilepsy.
2. Discuss the data and current trends in off-label use of the FDA-approved cannabidiol solution.
3. Identify cannabinoids’ role in the management of chronic conditions and orphan disease states.
4. List other cannabinoid pharmaceuticals currently under development.
Safe by Nature? Concerns with the Medical Use of Cannabinoids
5:00 PM

  • Lisa  Garrity, Pharm.D., BCPSSpeaker: Lisa Garrity, Pharm.D., BCPS
    Pharmacy Clinical Specialist in Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio
      View Biography

Learning Objectives
1. Identify potential developmental concerns with the use of cannabinoids in children and adolescents.
2. Distinguish the adverse effects associated with the use of specific cannabinoid derivatives in a given patient case.
3. Analyze potential interactions between cannabinoids and other pharmaceuticals for a given patient case.
Addressing Logistical Issues with the Medical Use of Cannabinoids
5:30 PM

  • Michael W. Barberio, Pharm.D., BCPPSSpeaker: Michael W. Barberio, Pharm.D., BCPPS
    Emergency Medicine Clinical Pharmacist Specialist, Children's Hospital Colorado, Aurora, Colorado
      View Biography

Learning Objectives
1. List strategies to address issues surrounding medical use of cannabinoids in healthcare facilities.
2. Discuss the effects of state legislations on medical use of cannabinoids.
3. Describe current approaches to obtain third-party coverage for labeled and unlabeled use of the FDA-approved cannabidiol solution.
4. Collect ideas and solutions for implementing at own practice-site through small group discussions revolving around logistics of medical cannabinoids use.